Tripod Therapeutics

Company Overview

Snapshot

Founded in September 2022 by Dr. Ido Livneh and Prof. Aaron Ciechanover, Tripod Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel cancer therapies.

Business overview

Tripod Therapeutics is a biopharmaceutical company specializing in the manipulation of proteasome dynamics for cancer treatment. Leveraging scientific research from Nobel Prize Laureate Prof. Aaron Ciechanover, the company is developing an orally available drug substance designed to regulate proteasome localization, inducing cancer cell death. Tripod Therapeutics has demonstrated the efficacy of its approach in various animal models of cancer and is advancing towards preclinical and clinical trials within the Drugs Discovery & Development sector, targeting the Pharmaceuticals market.

Company Intelligence Q&A

What is Tripod Therapeutics' core focus?

Tripod Therapeutics focuses on developing cancer therapies by harnessing proteasome dynamics, aiming to create orally available drug substances that regulate proteasome localization to induce cancer cell death.

Who are the founders of Tripod Therapeutics?

Tripod Therapeutics was founded by Dr. Ido Livneh and Prof. Aaron Ciechanover in September 2022.

What stage of development is Tripod Therapeutics currently in?

Tripod Therapeutics is currently in the Pre-Funding stage and its product is in R&D, with demonstrated efficacy in animal models and plans for preclinical and clinical trials.

What is the scientific basis for Tripod Therapeutics' approach?

The company's scientific foundation is based on comprehensive research conducted by Nobel Prize Laureate Prof. Aaron Ciechanover and his team, focusing on proteasome dynamics.

In which sector does Tripod Therapeutics primarily operate?

Tripod Therapeutics operates primarily in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.